HANIVA TECHNOLOGY LLC
To expedite the treatment and cure of cancer through patented therapy and drug delivery devices.
Haniva owns a patent for a novel method to treat cancer. We are patent pending for drug delivery devices. We are continuing the efforts in the Haniva Research & Development, ultimately leading to clinical trials and improving patient outcomes.
Haniva was awarded a US Patent In March, 2017 for the Combination Therapy of non-thermal plasma and any DNA damaging agent activated by hypoxia (Patent number 9,586,056). As of May, 2021, we also received patent approval for our combination therapy from the Australian government. While our original studies were performed with metastatic melanoma cells and tumors, the therapy shows efficacy in other cell lines including colon cancer, cervical carcinoma, and most recently, glioblastoma. The goals of the research are to use non-thermal plasma and hypoxia-inducible agents in a highly selective targeting approach for cancer cells. Our melanoma studies have already demonstrated a 90% reduction in tumor volume when human tumors are assayed in a mouse model. Furthermore, we have documented decreases in many genes associated with metastasis. We plan to test the therapeutic effects in a mouse model for metastasis. This therapeutic approach may prove applicable to a broad spectrum of tumor types.
Tumors can be treated directly on the surface (including squamous carcinoma, basal carcinoma, and melanoma). The primary target market is stage II and stage III melanomas which have a 12.5% and 25% recurrence rate, respectively. In addition, it can be used to inject the drug into the tumor while the non-thermal plasma is used directly on the tumor surface. The most promising use of the therapy is likely to be as an adjuvant therapy to treat the site of the wound bed after surgical removal of the tumor. This can be used to prevent a few single cells that may escape tumor resection from metastasizing. Furthermore, a combination of pharmaceutical agents can be used to increase the efficacy of the drug. We will continue to improve and develop products with the ultimate goal of eradicating cancer.